search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Women’s health


body of literature has identified factors that influence participation, including caregiving responsibilities, employment patterns, financial considerations and logistical constraints.4,6 Women are more likely to balance multiple roles, which can make participation in time-intensive, site-based studies more challenging. In addition, aspects of study design may


unintentionally exclude women. Eligibility criteria, including restrictions related to pregnancy or childbearing potential, have historically limited participation.7 Trust and representation also play an important role. Engagement with clinical research is influenced by whether individuals feel represented in both the study population and its leadership. Where there is a lack of diversity among investigators or limited visibility of relevant patient groups, participation may be less likely.8,9 These challenges are not experienced uniformly across populations. Women from ethnic minority backgrounds and socio- economically disadvantaged communities often face additional barriers, including historical mistrust in medical research, reduced access to research-active centres and lower representation within trial leadership. These overlapping factors can further limit engagement and participation. Importantly, these dynamics should not


be interpreted as a lack of willingness to participate. Rather, they reflect a misalignment between how trials are structured and how individuals engage with healthcare in practice.


What the evidence suggests about improvement Encouragingly, the evidence also points towards specific design and delivery factors that influence representation within clinical trials. Studies have shown that recruiting through outpatient and community-based settings achieve higher representation of women compared to those relying on inpatient or hospital-based recruitment pathways.6


This is


not simply a question of convenience. It reflects how study site selection and recruitment strategy determine which populations are visible, accessible and ultimately eligible for participation.


Other study design and operational factors


have also been associated with improved representation, including: l Eligibility criteria that avoid unnecessary exclusion of women, particularly in relation to reproductive status.


l The use of less traditional academic research sites.


l Protocol designs that reduce visit burden,


through decentralised or hybrid models.


l Follow-up strategies that incorporate remote monitoring and telehealth, reducing reliance on site attendance.


l Site selection strategies that extend beyond tertiary centres, enabling access to broader patient populations.


l Participant-informed study design, where protocol feasibility is assessed against broader participant constraints.


Taken together, these findings suggest that representation is not simply a function of recruitment effort, but of how studies are designed, located and delivered. Studies that combine community-based identification with remote monitoring and reduced visit burden have demonstrated improved participation among women compared with traditional tertiary-centre recruitment. By enabling participation through local access points and flexible follow-up, these models address structural barriers such as travel, time constraints and competing responsibilities. In doing so, they expand the population available for recruitment rather than relying on those already able to attend specialist research centres.9


In this sense, inclusion is


engineered upstream, through protocol and infrastructure decisions, rather than solved downstream through recruitment tactics.


A broader infrastructure question These observations raise a more fundamental question about the role of recruitment within the clinical research model. If participation is primarily approached as a point-in-time event, focused on identifying and enrolling individuals within a defined window, then engagement begins relatively late in the process. At that stage, potential participants are asked to make a decision without necessarily having an established relationship with the research environment, a clear understanding of its relevance, or confidence in the process.


An alternative perspective is to consider


participation as part of a longer-term continuum. In this model, engagement begins earlier, outside the immediate context of a specific study, and is sustained over time. Individuals are supported in understanding their health, developing trust in research processes and maintaining an ongoing connection with healthcare and research environments. This requires us to understand and engage the population before an individual protocol arrives, rather than beginning that relationship only when recruitment opens. This approach shifts the emphasis:


l From recruitment to engagement l From transactional interaction to relationship-based participation


l From site-centred models to community- based access points


l From study-specific activity to longitudinal interaction


In the context of cardiometabolic disease, where conditions are managed over extended periods and require sustained engagement, this model may offer particular advantages. It creates the potential to align research participation more closely with individuals’ existing health behaviours and motivations. Improving representation at the point of data generation is therefore critical to generating valid evidence at scale — not only for today’s studies, but for the integrity of the systems that will increasingly guide clinical research and care.


Beyond access: the role of perceived relevance Structural barriers such as time, travel, and caregiving responsibilities are well documented. However, they do not fully explain the persistent under-representation of women in cardiometabolic studies.


A less visible, but equally important factor is


perceived relevance. Many women living with cardiometabolic conditions are not aware that


November 2026 I www.clinicalservicesjournal.com 53


AntonioDiaz - stock.adobe.com


t


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71